NeuroMab™ Anti-ADAM17 Antibody(NRP-0422-P929)

Product Overview

Description

ADAM17 is a well-validated target, inhibitors against its active/catalytic site have failed clinical trials due to lack of specificity/efficacy and toxicity issues. The antibody provides a novel intervention strategy based on targeting the substrate-recognition domain of ADAM17 - which is essential for ADAM17 activity. By targeting this domain of ADAM17 instead of the catalytic site, the adverse side effects associated with prior attempts to target ADAM 17 for therapeutic applications may be avoided.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Human

Applications

Inhib; In Vitro

Relevant Diseases

Multiple Sclerosis; Tumor

Product Properties

Preservatives

BSA Free

Concentration

1mg/mL

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

ADAM17

Official Name

ADAM17

Full Name

ADAM Metallopeptidase Domain 17

Alternative Names

ADAM Metallopeptidase Domain 17; Tumor Necrosis Factor; Alpha; Converting Enzyme; Snake Venom-Like Protease; TNF-Alpha Convertase; EC 3.4.24.86; TACE; CSVP; Disintegrin And Metalloproteinase Domain-Containing Protein 17; ADAM Metallopeptidase Domain 18;